EUSA Pharma has completed the build of its executive management team and commercial infrastructure with the appointment of Iain McGill to the role of President, Europe and International.
EUSA, a specialty pharmaceutical company focused on oncology, pain control and critical care, is now present in over 80 countries, with teams covering the US and over 20 European territories including the major EU markets.
Mr McGill joins EUSA from Wyeth Pharmaceuticals, where he held the position of Vice President and Global Manager for the company’s transplantation business. Previously, he was the Head of Novartis’ Transplantation, Immunology and Infectious Diseases Business Unit in Canada, and was a Global Brand Director at Novartis’ headquarters in Switzerland.
Bryan Morton, EUSA Pharma’s President and Chief Executive Officer, said: “Since founding EUSA four years ago, we have made tremendous progress, raising over $300 million in investment funding, establishing a portfolio of eight marketed and four pipeline products, and building a strong commercialisation platform on both sides of the Atlantic.
“Iain’s leadership skills, and track record of growing specialist pharmaceutical businesses, will prove invaluable as we complete EUSA’s transition from a development-stage company to a world leader in its field.”
Commenting on his appointment, Iain McGill added: “Having seen the team at EUSA build a great company in a very short period of time, I am delighted to join them as we drive the business to the next level. With an infrastructure now in place that can rival even our biggest competitors, EUSA is well positioned to continue its rapid development.
“I welcome the opportunity to contribute to that progress, as we focus on aggressive organic growth and further product in-licensing and acquisition.”